Laser Optofluidics in Fighting Multiple Drug Resistance

Author(s): Ruxandra Pirvulescu, Mihaela Oana Romanitan and Alina Popa- Cherecheanu

DOI: 10.2174/9781681084985117010008

Multiple Drug Resistance: An Up-Date

Pp: 112-137 (26)

Buy Chapters

* (Excluding Mailing and Handling)

  • * (Excluding Mailing and Handling)

Abstract

SHS investigation development is considered from the geographical and historical viewpoint. 3 stages are described. Within Stage 1 the work was carried out in the Department of the Institute of Chemical Physics in Chernogolovka where the scientific discovery had been made. At Stage 2 the interest to SHS arose in different cities and towns of the former USSR. Within Stage 3 SHS entered the international scene. Now SHS processes and products are being studied in more than 50 countries.

Abstract

Multiple Drug Resistance (MDR) is acquired by bacteria, viruses, fungi, parasites and malignant tumours at interaction with antibiotics/medicines of old or new generation. Here is presented an up-date of MDR reported on bacteria, viruses, fungi, parasites and tumors, in this last field with emphasis on ophthalmology and neurology/neurosurgery. Multidrug resistant organisms exhibit in vitro resistance to one or more antimicrobial agents. One cause is the increasing use and misuse of antibiotics on humans and animals. Whereas particular bacteria are naturally resistant to some antibiotics, MDR occurs in other cases by accumulation of resistant plasmids and/or of genes, each gene determining resistance to a specific agent. The action of efflux pumps able to pump out more than one drug type is also a possible mechanism involved in MDR. In general, MDR is the most important “process” by which tumors acquire resistance to drugs during chemotherapy. Bacterial resistance to antibiotics used in ophthalmology has been reported since more than 10 years showing that several bacteria resistant to antibiotics were found in isolates from ocular infections. In neuroscience, development of new therapies to treat brain infections is more difficult. The most important cause of failure in developing new drugs for treating brain diseases is the existence and action of blood brain barrier (BBB). Brain tumors have usually poor prognosis and due to BBB, drug delivery to brain tumors is difficult. Some studies mention that BBB is involved in drug restriction to different brain neoplasias. The chapter concludes about the need to improve the arsenal conceived to overcome MDR acquired by different biological targets.

Recommended Chapters

We recommend

Favorable 70-S: Investigation Branching Arrow

Authors:Bentham Science Books